A phase 3 randomized controlled trial demonstrated that fecal microbiota transplantation (FMT) was noninferior to vancomycin therapy in treating primary Clostridioides difficile infection. The FMT group showed higher clinical cure rates and lower disease recurrence compared to the vancomycin group, suggesting FMT may be superior. The study suggests a potential shift toward microbiome restoration as the first-line therapy for Clostridioides difficile infection.

Source: Annals of Internal Medicine and Editorial